Abstract
We divide antiarrhythmic medication according to their influence on membraned action potential and on mechnisms of development of arrhythmias. The aim of therapy is relieving symptoms, managing haemodynamic complications and influencing prognosis.
Betablockers have prognostic value in patients with malignant ventricular arrhythmias and after myocardial infarction.